Neuroendocrine and Adrenal Tumors

Withdrawn

• Conditions: Neuroendocrine Tumors; Adrenal Tumor

• Registration Number: NCT04432532
• Lead Sponsor: University of Pennsylvania

Brief Summary

This is a prospective study of rare neuroendocrine and adrenal tumors. Subjects will be enrolled via informed consent, and blood and/or saliva and tissue will be collected. This is designed to work in conjunction with IRB#831990 which is a retrospective protocol. The University of Pennsylvania will be a contributing site with the University of Michigan as the coordinating site for the A5 alliance, a multi-institutional collaborative designed to study neuroendocrine and adrenal tumors.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-03-09
• Study First Submitted QC: 2020-06-12
• Study First Posted: 2020-06-16
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-06
• Last Update Posted: 2025-02-10
• Study Start: 2025-12-01
• Primary Completion: 2027-01-01
• Study Completion: 2028-01-01

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: 999

Inclusion Criteria

• diagnosed with neuroendocrine and/or an adrenal tumor

Exclusion Criteria

• pregnant women
• prisoners
• people under the age of 18

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Survival	10 years

Secondary Outcome Measures

Name	Time	Method
Tumor Recurrence	10 years	We want to record recurrences in our patient population